And the increased expression of inhibitory receptors was a key feature of this phenomenon, consistent with the increased expression of TIGIT on CD4+ T cells of HBV-HCC patients in our study, this provides a potential rationale for developing therapeutic modalities targeting TIGIT to prevent HCC progression and promote survival. The gene discussed is CD4; the disease is hepatocellular carcinoma.